000164041 001__ 164041
000164041 005__ 20230915090545.0
000164041 0247_ $$2doi$$a10.1016/j.jcrc.2022.154051
000164041 0247_ $$2pmid$$apmid:35526506
000164041 0247_ $$2ISSN$$a0883-9441
000164041 0247_ $$2ISSN$$a1557-8615
000164041 0247_ $$2altmetric$$aaltmetric:128332203
000164041 037__ $$aDZNE-2022-00704
000164041 041__ $$aEnglish
000164041 082__ $$a610
000164041 1001_ $$aScherer, Clemens$$b0
000164041 245__ $$aPropofol versus midazolam sedation in patients with cardiogenic shock - an observational propensity-matched study.
000164041 260__ $$aPhiladelphia, Pa.$$bSaunders$$c2022
000164041 3367_ $$2DRIVER$$aarticle
000164041 3367_ $$2DataCite$$aOutput Types/Journal article
000164041 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1653309992_20932
000164041 3367_ $$2BibTeX$$aARTICLE
000164041 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164041 3367_ $$00$$2EndNote$$aJournal Article
000164041 520__ $$aBenzodiazepines are recommended as first line sedative agent in ventilated cardiogenic shock patients, although data regarding the optimal sedation strategy are sparse. The aim of this study was to investigate the hemodynamic effects of propofol versus midazolam sedation in our cardiogenic shock registry.Mechanically ventilated patients suffering from cardiogenic shock were retrospectively enrolled from the cardiogenic shock registry of the university hospital of Munich. 174 patients treated predominantly with propofol were matched by propensity-score to 174 patients treated predominantly with midazolam.Catecholamine doses were similar on admission but significantly lower in the propofol group on days 1-4 of ICU stay. Mortality rate was 38% in the propofol and 52% in the midazolam group after 30 days (p = 0.002). Rate of ≥BARC3 bleeding was significantly lower in the propofol group compared to the midazolam group (p = 0.008). Sedation with midazolam was significantly associated with ICU mortality.In this observational cohort study, sedation with propofol in comparison to midazolam was linked to a reduced dose of catecholamines, decreased mortality and bleeding rates for patients with cardiogenic shock. Based on this study and in contrast to current recommendations, propofol should be given consideration for sedation in cardiogenic shock patients.
000164041 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000164041 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164041 650_7 $$2Other$$aAnesthetics
000164041 650_7 $$2Other$$aCardiogenic shock
000164041 650_7 $$2Other$$aMidazolam
000164041 650_7 $$2Other$$aPropofol
000164041 650_7 $$2Other$$aSedation
000164041 650_7 $$2Other$$aVA-ECMO
000164041 650_2 $$2MeSH$$aConscious Sedation
000164041 650_2 $$2MeSH$$aHumans
000164041 650_2 $$2MeSH$$aHypnotics and Sedatives: therapeutic use
000164041 650_2 $$2MeSH$$aMidazolam: therapeutic use
000164041 650_2 $$2MeSH$$aPropofol: adverse effects
000164041 650_2 $$2MeSH$$aRespiration, Artificial
000164041 650_2 $$2MeSH$$aRetrospective Studies
000164041 650_2 $$2MeSH$$aShock, Cardiogenic: drug therapy
000164041 7001_ $$aKleeberger, Jan$$b1
000164041 7001_ $$aKellnar, Antonia$$b2
000164041 7001_ $$aBinzenhöfer, Leonhard$$b3
000164041 7001_ $$aLüsebrink, Enzo$$b4
000164041 7001_ $$aStocker, Thomas J$$b5
000164041 7001_ $$0P:(DE-2719)9001700$$aBerghoff, Stefan A$$b6$$udzne
000164041 7001_ $$aKeutner, Alix$$b7
000164041 7001_ $$aThienel, Manuela$$b8
000164041 7001_ $$aDeseive, Simon$$b9
000164041 7001_ $$aStark, Konstantin$$b10
000164041 7001_ $$aBraun, Daniel$$b11
000164041 7001_ $$aOrban, Mathias$$b12
000164041 7001_ $$aPetzold, Tobias$$b13
000164041 7001_ $$aBrunner, Stefan$$b14
000164041 7001_ $$aHagl, Christian$$b15
000164041 7001_ $$aHausleiter, Jörg$$b16
000164041 7001_ $$aMassberg, Steffen$$b17
000164041 7001_ $$aOrban, Martin$$b18
000164041 773__ $$0PERI:(DE-600)2041640-4$$a10.1016/j.jcrc.2022.154051$$gVol. 71, p. 154051 -$$p154051$$tJournal of critical care$$v71$$x0883-9441$$y2022
000164041 909CO $$ooai:pub.dzne.de:164041$$pVDB
000164041 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001700$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000164041 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000164041 9141_ $$y2022
000164041 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000164041 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000164041 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-29$$wger
000164041 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CRIT CARE : 2021$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-29
000164041 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-29
000164041 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x0
000164041 980__ $$ajournal
000164041 980__ $$aVDB
000164041 980__ $$aI:(DE-2719)1110008
000164041 980__ $$aUNRESTRICTED